Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pelitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 14/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pelitinib SCHEMBL29623744 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29385637 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29352012 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93756 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93757 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL8132957 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL6382792 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL12641715 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL10108217 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL14944414 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4724 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122005813-A | Targeted treatment of cancers with deregulated fibroblast growth factor receptor signaling | 法码科思莫斯控股有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4363043-B1 | COMPOSITIONS FOR USE IN METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2026-04-22 | — | — | EP | claimed |
| EP-4724151-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724150-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-12594421-B2 | Compositions and methods for increasing cancer cell sensitivity to alternating electric fields | NOVOCURE GMBH (CH) | 2026-04-07 | — | — | US | claimed |
| US-20260091021-A1 | COMBINATION THERAPIES COMPRISING PANOBINOSTAT FOR THE TREATMENT OF CHOLANGIOCARCINOMA | SEALD AS (NO) | 2026-04-02 | — | — | US | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| CN-110325212-B | Farnesyl transferase inhibitors for use in methods of treating cancer | 库拉肿瘤学公司 | 2022-03-22 | — | — | CN | claimed |
| EP-3965896-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | The United States Government as Represented by the Department of Veterans Affairs (US) | 2022-03-16 | — | — | EP | claimed |
| EP-3964513-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | Novartis AG (CH) | 2022-03-09 | — | — | EP | claimed |
| EP-3955928-A1 | COMPOUNDS WITH ANTI-TUMOR ACTIVITY AGAINST CANCER CELLS BEARING TYROSINE KINASE INHIBITOR RESISTANT EGFR MUTATIONS | Board of Regents, The University of Texas System (US) | 2022-02-23 | — | — | EP | claimed |
| WO-2022029628-A1 | COMPOSITIONS AND METHODS FOR INCREASING CANCER CELL SENSITIVITY TO ALTERNATING ELECTRIC FIELDS | NOVOCURE GMBH (CH) | 2022-02-10 | — | — | WO | claimed |
| US-20220041704-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF EGF/EGFR PATHWAY IN COMBINATION WITH TYROSINE KINASE INHIBITORS | IN3BIO LTD. (BM) | 2022-02-10 | — | — | US | claimed |
| CN-113975393-A | Methods of treating gefitinib resistant cancers | 综合医院公司 | 2022-01-28 | — | — | CN | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
| CN-113952338-A | Methods of treating gefitinib resistant cancers | 综合医院公司 | 2022-01-21 | — | — | CN | claimed |
| CN-113952459-A | Methods of treating gefitinib resistant cancers | 综合医院公司 | 2022-01-21 | — | — | CN | claimed |